Advertisement

Induced pluripotent stem cells in multiple system atrophy: recent developments and scientific challenges

  • Alain Ndayisaba
  • Marcos Herrera-Vaquero
  • Gregor K. Wenning
  • Nadia StefanovaEmail author
Open Access
Review

Abstract

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disease, with no known genetic cause to date. Oligodendroglial α-synuclein accumulation, neuroinflammation, and early myelin dysfunction are hallmark features of the disease and have been modeled in part in various preclinical models of MSA, yet the pathophysiology of MSA remains elusive. Here, we review the role and scientific challenges of induced pluripotent stem cells in the detection of novel biomarkers and druggable targets in MSA.

Keywords

α-Synuclein iPSCs Stem cells Multiple system atrophy Parkinson’s disease 

Introduction

Multiple system atrophy (MSA) is a rapidly progressive and fatal neurodegenerative disease, the etiology of which is currently unknown. Clinically, variable combinations of autonomic dysfunction, parkinsonism, and cerebellar or pyramidal tract dysfunction are observed, and according to the predominance of parkinsonian or cerebellar symptoms are classified into subtype MSA-P or MSA-C, respectively [1]. These syndromes, previously described as the distinct neurological entities Shy-Drager syndrome, olivopontocerebellar atrophy (OPCA), and striatonigral degeneration (SND), have been known under the collective term MSA since 1969 [2], but it was only in 1989 that neuropathological analyses confirmed the presence of so-called Papp–Lantos bodies, glial cytoplasmic inclusions (GCI), in MSA cases [3]. These proteinaceous, primarily oligodendroglial inclusions were shown to be α-synuclein (α-syn)-immunoreactive approximately 20 years ago [4, 5], distinguishing MSA from Parkinson’s disease (PD), dementia with Lewy bodies, and pure autonomic failure, which predominantly exhibit neuronal cytoplasmic and dendritic inclusions containing α-syn as the main component as well [6, 7].

From an epidemiological standpoint, MSA represents an orphan disease with an estimated mean incidence of 0.6–0.7 cases per 100,000 person-years [8]. In the Western Hemisphere, 70–80% of MSA patients are diagnosed with MSA-P [9, 10], whereas in Asian populations MSA-C is found in 67–84%, with a mixed phenotype observed more frequently than in western countries [11, 12]. In patients presenting with parkinsonism or cerebellar ataxia, autonomic failure is a criterion for diagnosis of probable MSA [13]. Currently, diagnosis of definite MSA is made upon postmortem detection of widespread α-syn positive GCIs, the histopathological hallmark of the disease [3], which reflects the difficulty in diagnosing MSA with its variable clinical manifestations [1]. Prior to motor symptom onset, 20–75% of patients experience a prodromal phase, which lasts from several months to years and is characterized by autonomic failure affecting cardiovascular, respiratory, urogenital, gastrointestinal, and sudomotor functions [14]. In addition, rapid eye movement (REM) sleep behavior disorder (RBD) is frequently observed in the premotor stage of α-synucleinopathies, with more than half of patients reporting RBD prior to motor onset, and is present in up to 88% of patients diagnosed with probable MSA [15]. Intriguingly, dermal phospho-α-syn deposits have been detected in isolated RBD cases, whereas no deposits were found in healthy controls [16]. This is supported by a short report by Gaig et al. of one pathologically confirmed MSA case with a long-standing history of stridor, RBD, and autonomic symptoms without parkinsonism or cerebellar signs [17]. Mean age at motor symptom onset is 56.2 ± 8.4 years, with no difference in sex distribution, and median survival is 6–10 (9.8) years [18, 19, 20].

The etiology of MSA is still elusive. A complex interaction incorporating genetic predisposition and environmental factors is suggested to drive disease initiation and progression, as familial aggregation following an autosomal dominant or recessive inheritance pattern has been reported in several European and Japanese families [21, 22]. However, MSA is generally considered a sporadic disease with no confirmed risk factors to date [1]. Loss of function mutation in the coenzyme Q2 (COQ2) gene encoding the COQ10-synthesizing enzyme in Japanese familial and sporadic cases and discordant loss of copy numbers of (src homology 2 domain containing)-transforming protein 2 (SHC2) in monozygotic twins and Japanese patients with sporadic MSA have been reported predominantly for MSA-C; however, this was not confirmed in other populations [23, 24, 25]. No mutation of the gene coding for α-syn, SNCA, has been found in sporadic MSA; intriguingly, however, oligodendroglial inclusions are detected in cases of familial PD harboring the SNCA mutations [26]. Moreover, clinical features similar to MSA have been observed in some cases [27], indicating a link between oligodendroglial inclusion pathology and MSA phenotype.

MSA: human postmortem findings

At postmortem examination, neurodegeneration of anatomical areas corresponding to clinical symptoms is observed and therefore varies; however, in cases of predominant parkinsonism, striatonigral degeneration, manifesting macroscopically as atrophy and dark discoloration of the putamen, is found [28, 29]. The cerebellar subtype, on the other hand, presents pathologically with olivopontocerebellar atrophy including the cerebellum, middle cerebellar peduncle, and pontine base [28, 29].

On a cellular basis, MSA is characterized by widespread α-syn immunoreactive inclusion pathology found primarily in oligodendrocytes and to a lesser extent in neurons and other glia. In addition, myelin dysfunction, neuronal loss, and axonal degeneration and microglial activation are present in the brain [28].

The mechanism underlying GCI formation is still uncertain, as mature oligodendrocytes express only low basal levels of α-syn. Hypotheses revolve around (1) increased oligodendroglial α-syn expression in the disease [30], although several studies have failed to show aberrant expression of SNCA mRNA in oligodendrocytes [31, 32, 33]; or (2) cell-to-cell transmission of neuronal α-syn to dysfunctional oligodendrocytes not capable of degrading α-syn that has been taken up [34, 35]. In addition, α-syn in MSA also forms glial nuclear inclusions, neuronal cytoplasmic, and nuclear and dendritic inclusions, as well as astroglial cytoplasmic inclusions [36]. In the early stages of neurodegeneration, oligodendroglial dysfunction is observed, which precedes α-syn pathology. Prominent findings at this stage are myelin degeneration reflected by myelin basic protein (MBP) degradation and aberrant composition of myelin lipids, relocation of microtubule polymerization-promoting protein p25α/TPPP to the swollen oligodendroglial soma, and consequently reduced neurotrophic support [28, 37, 38]. GCI density is positively correlated with neuronal loss, and an increase is observed with disease duration [39]. The most severely affected areas include the putamen, caudate nuclei, substantia nigra, pontine and medullary tegmental nuclei, and inferior olive and cerebellar white matter, as well as motor cortex and globus pallidus, and to a lesser extent cingulate cortex, hypothalamus, nucleus basalis of Meynert, thalamus, subthalamus, and pontine tegmentum [40]. More recently, stereological studies reported the occurrence of neocortical atrophy affecting frontal and temporal lobes following degeneration of the basal ganglia [41, 42, 43]. Cognitive decline and impaired executive function have been reported in MSA, and it is suggested that focal fronto-striatal degeneration rather that widespread cortical atrophy accounts for the symptoms [44].

Synuclein pathology is suggested to trigger astro- and microglial changes toward an activated and reactive state, which in turn favors neurodegeneration [45]. In MSA brains, more astrocytes and microglia are found in the frontal and parietal cortex, whereas the total number of oligodendrocytes in the neocortex is unaffected [43], reflecting pathological changes consistent with neuroinflammation, one of the drivers of MSA pathogenesis. In contrast to PD, astrogliosis is positively correlated with synuclein pathology in MSA and severity of neurodegeneration [46, 47]. Monoamine oxidase B (MAO-B), a biomarker of astrogliosis, is significantly increased in the putamen (+83%) and correlates positively with α-syn accumulation, whereas a less dramatic increase in MAO-B (+10%) in the substantia nigra correlates with membrane-bound α-syn [48]. MAO-A, on the other hand, is decreased only in the atrophic putamen in the case of MSA (−27%), while in the substantia nigra in PD, no change is observed, thus highlighting aberrant astrocyte behavior in MSA compared to PD. The role of microglia has been studied extensively in neurodegenerative disorders, and yet its full impact on disease pathogenesis is not completely clear, as both pro- and anti-inflammatory properties have been attributed to the ‘macrophages of the brain’, surveying the central nervous system in their resting state. In MSA, microglia become activated in response to an increasing load of misfolded α-syn, which in turn contributes heavily to disease pathogenesis via secretion of pro-inflammatory factors [49]. Microglial activation accompanies GCI pathology in white matter [50], but interestingly, loss of p25α/TPPP immunoreactivity and loss of MBP density correlate strongly with microgliosis as a marker of tract degeneration [51]. Activation of TLR4 and myeloperoxidase has been reported in microglia in MSA [49, 52, 53]. Microglia can be divided into two distinct phenotypes, the pro-inflammatory M1 and the anti-inflammatory M2 phenotype [54]. M1-type microglia is detected more abundantly at the end stage of disease and may represent a consequence of GCIs in MSA [28].

In vitro and in vivo models of MSA: relevance and limitations

Studies on the pathogenic mechanisms of MSA downstream of α-syn aggregation have been carried out in different in vivo and in vitro models, as shown in Fig. 1 [55, 56], in addition to neurotoxin-induced lesions of the striatonigral system [57, 58]. Transgenic oligodendroglial overexpression of α-syn under the proteolipid protein (PLP) promoter results in region-selective neuronal loss associated with early autonomic dysfunction and motor impairment, thereby providing evidence for a causal role of oligodendroglial inclusion formation in the degenerating brain in MSA [59, 60]. The causative role of GCI-like pathology in neurodegeneration has been further supported by studies in additional transgenic models applying alternative oligodendroglial promoters [61, 62, 63, 64]. Several in vitro models [65, 66, 67, 68] have also been used to study MSA, providing some insight into pathological mechanisms at the molecular level.
Fig. 1

In vivo and in vitro models of MSA. 6-OHDA 6-hydroxydopamine, QA quinolinic acid, 3-NP 3-nitropropionic acid, MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, i.v. intravenous, i.p. intraperitoneal, MBP myelin basic protein, CNP 2′,3′-cyclic nucleotide 3′-phosphodiesterase, PLP proteolipid protein, iPSC induced pluripotent stem cell, PBMC peripheral blood mononuclear cell, OPC oligodendrocyte progenitor cell, OL oligodendrocyte, DAergic dopaminergic

These in vivo and in vitro models have been crucial for elucidation of disease mechanisms and continue to represent an invaluable tool for basic research. However, a major limitation in understanding the human disease remains the mechanistic recapitulation of MSA pathology in the available models linked to the lack of knowledge on the initial disease trigger(s).

In recent years, however, the study of patient-specific brain cells derived from easily accessible peripheral tissue via induced pluripotent stem cell (iPSC) technology has flourished, providing a promising template for the study of neurodegenerative diseases and guided drug discovery [69, 70, 71].

Induced pluripotent stem cells as a disease model

Pluripotent stem cells are characterized by their ability to continuously self-renew and to give rise to cells of the three primary germ layers. These so-called embryonic stem cells (ESCs), which occur naturally only in embryos, have been studied since their first derivation from the mouse and human blastocyst [72, 73], with relevance for the modeling of neurodegenerative diseases and development of alternative sources for replacement therapies [74]. However, ethical controversies and limited availability have impeded progress in this field [75]. In 2006, Shinya Yamanaka ushered in a paradigm shift when he showed for the first time the potential for somatic cells to be reprogrammed to a pluripotent state resembling embryonic stem cells, via application of four transcription factors—Oct3/4, Sox2, Klf-4, and c-Myc—which are thus termed induced pluripotent stem cells [76, 77]. Since then, easily accessible peripheral tissue has been used to generate iPSCs by (i) delivery of transcription factors via genome-integrating lenti- or retroviruses; (ii) delivery of transcription factors via non-integrating adenovirus or sendai virus, or (iii) non-viral reprogramming methods including mRNA, miRNA infection/transfection, PiggyBac transposons, minicircle vectors, and episomal plasmids [78]. Subsequent differentiation of patient-derived pluripotent cells reprogrammed into neural cell types has been employed in modeling specific diseases. The directed differentiation of stem cells to specific cell phenotypes is facilitated by the precisely timed addition of molecules influencing cell fate during various stages of neurodevelopment [79].

Midbrain dopaminergic neurons, for example, have been efficiently generated from ESCs [80] and later iPSCs [81, 82, 83] to enable modeling of the α-synucleinopathy PD. Although initial differentiation of PD patient-derived iPSCs did not reveal a disease-related phenotype [84], subsequent studies on cell lines harboring PD-causing or PD-associated mutations detected morphological and subcellular changes such as reduced neurite outgrowth, dendrite degeneration and diminished microtubule stability [85, 86, 87]. In addition, increased susceptibility to stress of an oxidative or nitrosative nature [87, 88, 89, 90], increased levels of α-syn [91, 92] but also elevated α-syn aggregation and Lewy body deposition [90], and mitochondrial dysfunction has been observed [90, 91, 93, 94]. Dopaminergic neurons of individuals with sporadic PD carrying a mutation in the glucocerebrosidase (GBA) gene, show elevated α-syn levels, reduced dopamine storage and uptake, defective autophagic and lysosomal machinery and enhanced vulnerability to endoplasmic reticulum stress [95, 96, 97]. Intriguingly, in iPSC-derived neurons of monozygotic twins harboring the GBA N370S mutation and discordant for PD, altered susceptibility toward oxidative stress in the affected twin suggests the presence of disease-contributing factors other than the GBA mutation, which were preserved across the reprogramming and differentiation procedure [96]. Furthermore, researchers reported epigenetic alterations in dopaminergic neurons derived from patients with sporadic PD compared to healthy controls [98].

Efforts have been made to generate specific glial phenotypes. iPSC-derived oligodendrocytes have been generated to support studies on multiple sclerosis [99] and Pelizaeus–Merzbacher disease [100]. Astro- and microglia differentiation protocols have also recently been established [101, 102]. Whether the resultant patient-derived glial cells will reflect features seen in diseased brains remains to be tested.

iPSC technology to fill the gaps in modeling multiple system atrophy: current developments

In MSA, multiple neuronal and glial phenotypes are affected by the neurodegenerative process linked to α-syn misfolding and accumulation. First efforts have been made to apply the iPSC technology in MSA research (Fig. 1). Recent findings in primary cell cultures suggested a causal role of glia in the pathogenesis of MSA [103]. On the other hand, the origin of α-syn found in MSA oligodendrocytes is still elusive [30, 32, 104]. Djelloul et al. addressed this question by investigating α-syn and SNCA expression in rodent and human models [105]. A primary mixed culture including astrocytes, neurons, oligodendrocytes, and microglia was generated from the postnatal mouse forebrain, and oligodendrocyte progenitors positive for O4 were subsequently isolated. Quantification of α-syn and SNCA transcripts revealed a more than tenfold increase in the oligodendrocyte lineage compared to the whole primary culture. Upon maturation, however, α-syn and SNCA levels decreased substantially as oligodendrocytes started to express maturation markers such as 2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNPase), galactosylceramide (Gal-C), and MBP. To confirm that this effect was not the result of neuronal–oligodendroglial transfer within the culture, oligodendrocyte precursor cells (OPCs) were generated from mouse ESCs, exhibiting a similar outcome. In a next step, Djelloul et al. applied a modified protocol from Stacpoole et al. [106] to differentiate fibroblast-derived iPSCs from one patient each with MSA-P and MSA-C, one patient suffering from familial PD, and a healthy control into OPCs. After 60 days, oligodendrocyte progenitors—characterized by immunocytochemical confirmation of OPC markers and immature bipolar morphology—revealed α-syn expression in both healthy and diseased lines, with no significant difference between groups. Finally, human oligodendrocyte lineage nuclei were isolated from the pons of three healthy and three MSA postmortem brains to determine the presence of SNCA transcripts, which resulted in the detection of SNCA in one healthy and one diseased sample. This study provides compelling evidence for α-syn expression during oligodendrogliogenesis and subsequent downregulation following maturation in human tissue, complementing previous findings on a physiological occurrence of α-syn in oligodendroglial precursors in animal models [107]. As this downregulation was observed in MSA patient-derived cell lines as well, it is still unclear whether α-syn of oligodendroglial origin does play a role in disease and whether disease-specific features of MSA are partially erased during the whole process of reprogramming and targeted differentiation. Nevertheless, it may be interesting to investigate protein handling of MSA oligodendrocytes and the effects of exogenous addition of α-syn to oligodendrocytes. Kaji et al., for instance, found that the level of endogenous α-syn in primary OPCs from neonatal rats was increased upon the addition of synthetic preformed α-syn fibrils, due to autophagic impairment [108]. Furthermore, the exogenous addition of α-syn led to compromised expression of proteins involved in neuromodulation and myelination, an aspect which, if reproducible in human tissue, may shed great light on MSA pathogenesis.

The contribution of mitochondrial dysfunction to MSA pathogenesis is another aspect currently under discussion. A reduction in respiratory chain complex I activity has been shown in the skeletal muscle of MSA patients [109], whereas platelets and substantia nigra revealed no changes [110]. Mitochondrial dysfunction has also been investigated in MSA mouse models. Studies showed that striatal injection of succinate dehydrogenase inhibitor 3-nitropropionic acid in rats [56] or mitochondrial complex I inhibitor 1-methyl-4-phenylpyridinium ion (MPP+) in mice [111] induced extensive neuronal loss in the substantia nigra and striatum, as well as astrogliosis, accompanied by motor deficits resembling parkinsonism. The strongest evidence to date, however, is from the occurrence of COQ2 mutations in rare Japanese families and sporadic cases presenting predominantly as the cerebellar subtype of MSA [23]. To investigate the effects of functionally impaired variants of COQ2 on mitochondrial function, Nakamoto et al. examined iPSC-derived neurons from a patient with a compound heterozygous COQ2 mutation, an idiopathic MSA patient, and three control lines of diverse descent (Caucasian, African, and Japanese origin) [112]. In addition, an isogenic control was generated by site-specific gene correction of the cell line harboring the COQ2 mutation. In their work, they reprogrammed peripheral blood mononuclear cells into iPSCs, and following a battery of tests to confirm pluripotency and normal karyotype, selected cell clones were differentiated using three different methods to induce neural cells: (i) high-efficiency induction of neurons, (ii) induction of mid-hindbrain neurons [113], and (iii) induction of the three basic lineages of neural cells [114]. Mid- and hindbrain neurons were successfully generated with the latter two methods, representing an area severely affected in MSA-C. Neuronal subpopulations present in the culture included glutamatergic (VGLUT1 and VGLUT2), GABAergic, dopaminergic (tyrosine hydroxylase), and glycinergic (VGAT) neurons.

Mitochondrial integrity, which is expected to be impaired in subjects carrying a mutated COQ2 gene, was assessed by measuring the mean area of the inner mitochondrial membrane, which revealed a significant reduction in the COQ2-mutated MSA patient (MSA_mut) compared with the sporadic MSA patient (MSA_sp) and controls. In addition, COQ10 and vitamin E were quantified and showed reduced levels not only in MSA_mut, but also in the patient cell line carrying the corrected gene (MSA_corr). Changes in mitochondrial respiratory chain activity determined by oxygen consumption rate and extracellular acidification rate showed a significant decrease in MSA_mut and partially in MSA_sp compared to MSA_corr and controls.

Neurodegeneration is observed in the brainstem and striatum of MSA patients postmortem. Analysis of neurite length, however, a sign of neurodegeneration also shown in various iPSC-based models of neurodegeneration, did not reveal any differences between MSA and healthy control lines. Nakamoto and colleagues  then went on to investigate the cellular vulnerability of MSA-derived neurons compared to healthy control neurons using a glucose-free medium and galactose instead, which represents a stress condition. This forces a metabolic switch in cells toward oxidative phosphorylation-dependent ATP production, while glycolysis is inhibited. Staining for cleaved caspase 3 (a marker of apoptosis)-positive neurons in the stress condition was higher in MSA_mut neurons than in controls. MSA_sp showed a tendency for higher levels of apoptosis, and MSA_corr revealed a lower ratio of apoptotic cells compared with MSA_mut, but still significantly higher than in controls. COQ10 supplementation decreased the fraction of apoptotic neurons in MSA_mut, suggesting that low endogenous COQ10 levels are at least partially responsible for the cellular vulnerability observed. In conclusion, this study reveals that the correction of the COQ2 mutation ameliorated mitochondrial function and signs of neurodegeneration but was not able to rescue the cells completely when compared to healthy control lines, indicating that additional factors may come into play here. In addition, the experimental results in cells derived from an idiopathic MSA patient differed significantly from the patient harboring the mutation, therefore additional studies will be needed to identify if this difference is disease-specific or underlies the phenotypic variability between individuals with different genetic background.

Mitochondrial and autophagic dysfunction was also examined in iPSC-derived dopaminergic neurons from MSA patients and healthy controls by Monzio Compagnoni et al. [115]. Cell lines from two MSA-P, two MSA-C, and five healthy controls, among them the healthy monozygotic twin of one of the MSA-C patients (MSA_C1), were generated. In MSA_C2, a homozygous variant in the COQ2 gene (p.A43G) was found, which, according to a previous study using this patient’s cells [116], did not affect respiratory chain activity in muscle or COQ10 levels in muscle and fibroblasts. No other mutations associated with parkinsonism or ataxia were found in any cell line. Upon reprogramming of fibroblasts into iPSCs, dopaminergic neurons were generated according to a protocol by Zhang et al. [117]. To evaluate the maturation and identity of neurons, immunocytochemistry and real time-polymerase chain reaction for markers of dopaminergic neurons was performed, along with electrophysiology to assess post-synaptic activity, and sphingolipid composition was evaluated in three cell lines, confirming neuronal maturation. In order to assess cellular defects present in the MSA lines, western blot analysis of synaptic markers and tau, a neurite protein, was performed and showed decreased levels of synapsin I and tau in MSA patients. Intriguingly, the decrease in tau was not caused by a change in the microtubule-associated protein tau (MAPT) gene levels, and an assessment of α-syn levels did not reveal any differences between MSA and control cell lines. The extent of autophagic impairment was investigated by treating cell cultures with bafilomycin A (a V-ATPase inhibitor which inhibits the fusion of the autophagosome and the lysosome). An increased ratio of LC3-II after treatment to LC3-II basal levels was observed in controls, indicating more efficient autophagic flux, whereas LC3-II basal levels were elevated in MSA lines. Between the twins discordant for the disease, a similar but nonsignificant trend was observed. In addition, the activity of five lysosomal enzymes (GBA1, β-galactosidase, α-mannosidase, β-mannosidase and β-hexosaminidase) was measured, and only α- and β-mannosidase levels were reduced in MSA patients.

Also, mitochondrial dysfunction was investigated by evaluating the activity of respiratory chain complexes I, II, I + III, II + III, and IV by spectrophotometric analysis. The activity of complexes II, III, and II + III was strongly downregulated in MSA patients, but interestingly, the amount of the complexes was not found to be decreased, and was even increased in the case of complexes II and III, conceivably representing a compensatory mechanism. Levels of COQ10 important for mitochondrial activity were normal, yet COQ10-synthesizing enzymes PDSS1 (prenyl (decaprenyl) diphosphate synthase subunit 1), PDSS2, COQ4, and ADCK3 (coenzyme Q8 homolog) were increased. In MSA brain tissue representing the end stage of the disease, however, a decrease in PDSS1 and COQ5 was found [118, 119]. Thus, the authors hypothesize that mitochondrial dysfunction captured in vitro occurs early in disease, and upregulation of COQ10-synthesizing enzymes may represent a compensatory mechanism which fails at later disease stages. In addition, upregulation in MSA fibroblasts from the same group revealed higher levels of COQ5 and COQ7, supporting their findings in dopaminergic neurons [120]. Mitochondrial mass as determined by TOMM20, a mitochondrial structural protein, and mitochondrial DNA content was elevated, leading the authors to hypothesize that those changes in the autophagic system and mitochondria may be linked. They posited that mitochondrial dysfunction could be triggered by insufficient autophagy; thus mitophagy is impaired and senescent, and dysfunctional mitochondria accumulate to promote cellular dysfunction and autophagic dysregulation in a vicious cycle. In a next step, the authors aim to explore α-syn pathological behavior—although α-syn levels were normal in this study—lysosomal dysfunction, and mitophagy.

Scientific challenges

The first steps indicate the ability of the iPSC technology to reflect disease features and early events in the pathogenesis of MSA. However, first studies point toward significant challenges.

The iPSC-technology is clearly useful for studying the effects of disease-specific mutations in genetic neurodegenerative disorders by correcting the genetic defect with molecular tools [121]. However, sporadic diseases such as MSA lack specific genetic targets, and line-to-line variability due to differences in the genetic background of samples can be expected to hamper scientific interpretation. For years, researchers have tried to pinpoint differences between human ESCs and human iPSCs, but it appears that variability between one iPSC and one ESC line may be smaller than between two iPSC lines [122]. In addition, variability in the epigenetic landscape may result from differences in derivation method and culture history, and differences in cell type of origin may have a substantial impact in subsequent examinations of reprogrammed cells [123]. To overcome these hurdles, sibling lines with similar genetic background may be key for sporadic diseases, as they have been proven to display changes in genetic background despite environmental sources of variability including cell type of origin and derivation method [124]. Quantifiable phenotypic differences between patient and control in vitro in sporadic diseases are expected to be small [121]; therefore, the use of monozygous twin lines discordant for the disease, as in the experiment by Monzio Compagnoni et al., may shed light on disease-specific events. MSA represents a rare disease; therefore, iPSC lines, and especially sibling lines, are very sparse. A combined effort in the form of an international iPSC bio-bank would be instrumental in accelerating MSA research efforts.

As multiple systems and cell types are affected in MSA, co-culture of different cell types may facilitate the study of extracellular disease mechanisms such as α-syn transmission dynamics to answer the question of the origin of GCI-forming α-syn, and may also aid in determining the effects of cellular dysfunction on other cell types at disease onset. The use of more complex models such as 3D brain organoids to study cellular interactions may also be beneficial [125]. Importantly, Madhavan et al. recently demonstrated the generation of cortical oligospheres, an intriguing model for demyelinating diseases and oligodendrogliopathies [126], which may aid in dissecting the complex underlying pathogenesis in MSA. Moreover, both cortical- and midbrain-like organoids have been generated [127, 128] and may prove suitable for the study of MSA in a dish.

Conclusion

MSA has been studied in various disease models, and despite the elucidation of pathological mechanisms contributing to disease initiation and progression via glial overexpression of α-syn, the underlying pathogenesis of this sporadic disease largely remains an enigma. The emerging iPSC technology offers the unique opportunity to study the disease in the context of patient-specific genetic background. The first studies in MSA patient-specific neural cells revealed mitochondrial, lysosomal, and autophagic dysfunction in iPSC-derived neurons and dysregulation of oligodendroglia consistent with previous findings.

Challenges such as line-to-line variability owing to individual genetic composition might make it difficult to determine whether phenotypic differences between patient and control lines are truly disease-specific, but these may be overcome by increased sample size, technological advancements enabling more sophisticated analysis, and the utilization of sibling lines which exhibit comparable genetic make-up.

In addition, advances in stem cell technology now facilitate the creation of 3D brain structures or organoids and co-culture of multiple cell types to partially reconstruct the complex network of the human brain, which may ultimately aid in identifying druggable targets and their implications in a more sophisticated context, even though it may not be able to replace, but rather complement, functional readouts in in vivo models of neurodegeneration. Nevertheless, iPSC technology represents a promising approach toward two major goals: the detection of novel biomarkers to facilitate earlier diagnosis, and the elucidation of disease-modifying druggable targets.

Notes

Acknowledgments

Open access funding provided by Austrian Science Fund (FWF).

Funding

Funding was provided by Austrian Science Fund (Grant nos. F4414, I2102).

References

  1. 1.
    Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372:1375–1376CrossRefPubMedGoogle Scholar
  2. 2.
    Graham JG, Oppenheimer DR (1969) Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 32:28–34CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Papp MI, Kahn JE, Lantos PL (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94:79–100CrossRefPubMedGoogle Scholar
  4. 4.
    Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett 251:205–208CrossRefPubMedGoogle Scholar
  5. 5.
    Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H (1998) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249:180–182CrossRefPubMedGoogle Scholar
  6. 6.
    Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H (1998) Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol 96:445–452CrossRefPubMedGoogle Scholar
  7. 7.
    Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840CrossRefGoogle Scholar
  8. 8.
    Bower JH, Maraganore DM, McDonnell SK, Rocca WA (1997) Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49:1284–1288CrossRefPubMedGoogle Scholar
  9. 9.
    Gilman S, May SJ, Shults CW, Tanner CM, Kukull W, Lee VM, Masliah E, Low P, Sandroni P, Trojanowski JQ et al (2005) The North American multiple system atrophy study group. J Neural Transm (Vienna) 112:1687–1694CrossRefGoogle Scholar
  10. 10.
    Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M et al (2010) Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 25:2604–2612CrossRefPubMedGoogle Scholar
  11. 11.
    Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, Aiba I, Abe Y, Tamakoshi A, Doyu M et al (2002) Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 125:1070–1083CrossRefPubMedGoogle Scholar
  12. 12.
    Kim HJ, Jeon BS, Lee JY, Yun JY (2011) Survival of Korean patients with multiple system atrophy. Mov Disord 26:909–912CrossRefPubMedGoogle Scholar
  13. 13.
    Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK (2012) Premotor signs and symptoms of multiple system atrophy. Lancet Neurol 11:361–368CrossRefPubMedGoogle Scholar
  15. 15.
    Palma JA, Fernandez-Cordon C, Coon EA, Low PA, Miglis MG, Jaradeh S, Bhaumik AK, Dayalu P, Urrestarazu E, Iriarte J et al (2015) Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis. Clin Auton Res 25:69–75CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J et al (2017) Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease. Acta Neuropathol 133:535–545CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gaig C, Iranzo A, Tolosa E, Vilaseca I, Rey MJ, Santamaria J (2008) Pathological description of a non-motor variant of multiple system atrophy. J Neurol Neurosurg Psychiatry 79:1399–1400CrossRefPubMedGoogle Scholar
  18. 18.
    Quinn N (1989) Multiple system atrophy—the nature of the beast. J Neurol Neurosurg Psychiatry Suppl:78–89CrossRefPubMedGoogle Scholar
  19. 19.
    Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Köllensperger M, Goebel G, Pfeiffer KP, Barone P et al (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12:264–274CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Krismer F, Wenning GK (2017) Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat Rev Neurol 13:232–243CrossRefPubMedGoogle Scholar
  21. 21.
    Stemberger S, Scholz SW, Singleton AB, Wenning GK (1924) Genetic players in multiple system atrophy: unfolding the nature of the beast. Neurobiol Aging 2011(32):1924.e1925-1914Google Scholar
  22. 22.
    Itoh K, Kasai T, Tsuji Y, Saito K, Mizuta I, Harada Y, Sudoh S, Mizuno T, Nakagawa M, Fushiki S (2014) Definite familial multiple system atrophy with unknown genetics. Neuropathology 34:309–313CrossRefPubMedGoogle Scholar
  23. 23.
    Collaboration M-SAR (2013) Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 369:233–244CrossRefGoogle Scholar
  24. 24.
    Sasaki H, Emi M, Iijima H, Ito N, Sato H, Yabe I, Kato T, Utsumi J, Matsubara K (2011) Copy number loss of (src homology 2 domain containing)-transforming protein 2 (SHC2) gene: discordant loss in monozygotic twins and frequent loss in patients with multiple system atrophy. Mol Brain 4:24CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ferguson MC, Garland EM, Hedges L, Womack-Nunley B, Hamid R, Phillips JA, Shibao CA, Raj SR, Biaggioni I, Robertson D (2014) SHC2 gene copy number in multiple system atrophy (MSA). Clin Auton Res 24:25–30CrossRefPubMedGoogle Scholar
  26. 26.
    Fujishiro H, Imamura AY, Lin WL, Uchikado H, Mark MH, Golbe LI, Markopoulou K, Wszolek ZK, Dickson DW (2013) Diversity of pathological features other than Lewy bodies in familial Parkinson’s disease due to SNCA mutations. Am J Neurodegener Dis 2:266–275PubMedPubMedCentralGoogle Scholar
  27. 27.
    Gwinn K, Devine MJ, Jin LW, Johnson J, Bird T, Muenter M, Waters C, Adler CH, Caselli R, Houlden H et al (2011) Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by α-synuclein triplication (Iowa kindred). Mov Disord 26:2134–2136CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Jellinger KA (2018) Multiple system atrophy: an oligodendroglioneural synucleinopathy1. J Alzheimers Dis 62:1141–1179CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ahmed Z, Asi YT, Sailer A, Lees AJ, Houlden H, Revesz T, Holton JL (2012) The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 38:4–24CrossRefPubMedGoogle Scholar
  30. 30.
    Asi YT, Simpson JE, Heath PR, Wharton SB, Lees AJ, Revesz T, Houlden H, Holton JL (2014) Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia 62:964–970CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ozawa T, Okuizumi K, Ikeuchi T, Wakabayashi K, Takahashi H, Tsuji S (2001) Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol 102:188–190PubMedGoogle Scholar
  32. 32.
    Miller DW, Johnson JM, Solano SM, Hollingsworth ZR, Standaert DG, Young AB (2005) Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm (Vienna) 112:1613–1624CrossRefGoogle Scholar
  33. 33.
    Jin H, Ishikawa K, Tsunemi T, Ishiguro T, Amino T, Mizusawa H (2008) Analyses of copy number and mRNA expression level of the alpha-synuclein gene in multiple system atrophy. J Med Dent Sci 55:145–153PubMedGoogle Scholar
  34. 34.
    Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E (2014) Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 62:387–398CrossRefPubMedGoogle Scholar
  35. 35.
    Stefanova N, Kaufmann WA, Humpel C, Poewe W, Wenning GK (2012) Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Acta Neuropathol 124:51–65CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Wenning GK, Jellinger KA (2005) The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol 109:129–140CrossRefPubMedGoogle Scholar
  37. 37.
    Song YJ, Lundvig DM, Huang Y, Gai WP, Blumbergs PC, Højrup P, Otzen D, Halliday GM, Jensen PH (2007) p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 171:1291–1303CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Abati E, Di Fonzo A, Corti S (2018) In vitro models of multiple system atrophy from primary cells to induced pluripotent stem cells. J Cell Mol Med 22:2536–2546CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Halliday GM, Holton JL, Revesz T, Dickson DW (2011) Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 122:187–204CrossRefPubMedGoogle Scholar
  40. 40.
    Dickson DW (2012) Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med.  https://doi.org/10.1101/cshperspect.a009258 CrossRefGoogle Scholar
  41. 41.
    Brenneis C, Egger K, Scherfler C, Seppi K, Schocke M, Poewe W, Wenning GK (2007) Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. J Neurol 254:191–196CrossRefPubMedGoogle Scholar
  42. 42.
    Armstrong RA, Lantos PL, Cairns NJ (2005) Multiple system atrophy: laminar distribution of the pathological changes in frontal and temporal neocortex—a study in ten patients. Clin Neuropathol 24:230–235PubMedGoogle Scholar
  43. 43.
    Salvesen L, Winge K, Brudek T, Agander TK, Løkkegaard A, Pakkenberg B (2017) Neocortical neuronal loss in patients with multiple system atrophy: a stereological study. Cereb Cortex 27:400–410PubMedGoogle Scholar
  44. 44.
    Fiorenzato E, Weis L, Seppi K, Onofrj M, Cortelli P, Zanigni S, Tonon C, Kaufmann H, Shepherd TM, Poewe W et al (2017) Brain structural profile of multiple system atrophy patients with cognitive impairment. J Neural Transm (Vienna) 124:293–302CrossRefGoogle Scholar
  45. 45.
    Vieira BD, Radford RA, Chung RS, Guillemin GJ, Pountney DL (2015) Neuroinflammation in multiple system atrophy: response to and cause of α-synuclein aggregation. Front Cell Neurosci 9:437CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Song YJ, Halliday GM, Holton JL, Lashley T, O’Sullivan SS, McCann H, Lees AJ, Ozawa T, Williams DR, Lockhart PJ, Revesz TR (2009) Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol 68:1073–1083CrossRefPubMedGoogle Scholar
  47. 47.
    Tong J, Ang LC, Williams B, Furukawa Y, Fitzmaurice P, Guttman M, Boileau I, Hornykiewicz O, Kish SJ (2015) Low levels of astroglial markers in Parkinson’s disease: relationship to α-synuclein accumulation. Neurobiol Dis 82:243–253CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Tong J, Rathitharan G, Meyer JH, Furukawa Y, Ang LC, Boileau I, Guttman M, Hornykiewicz O, Kish SJ (2017) Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. Brain 140:2460–2474CrossRefPubMedGoogle Scholar
  49. 49.
    Stefanova N, Reindl M, Neumann M, Kahle PJ, Poewe W, Wenning GK (2007) Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord 22:2196–2203CrossRefPubMedGoogle Scholar
  50. 50.
    Ishizawa K, Komori T, Arai N, Mizutani T, Hirose T (2008) Glial cytoplasmic inclusions and tissue injury in multiple system atrophy: a quantitative study in white matter (olivopontocerebellar system) and gray matter (nigrostriatal system). Neuropathology 28:249–257CrossRefPubMedGoogle Scholar
  51. 51.
    Rohan Z, Milenkovic I, Lutz MI, Matej R, Kovacs GG (2016) Shared and distinct patterns of oligodendroglial response in α-synucleinopathies and tauopathies. J Neuropathol Exp Neurol 75:1100–1109CrossRefPubMedGoogle Scholar
  52. 52.
    Stefanova N, Georgievska B, Eriksson H, Poewe W, Wenning GK (2012) Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox Res 21:393–404CrossRefPubMedGoogle Scholar
  53. 53.
    Brudek T, Winge K, Agander TK, Pakkenberg B (2013) Screening of Toll-like receptors expression in multiple system atrophy brains. Neurochem Res 38:1252–1259CrossRefPubMedGoogle Scholar
  54. 54.
    Tang Y, Le W (2016) Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol 53:1181–1194CrossRefPubMedGoogle Scholar
  55. 55.
    Wenning GK, Granata R, Laboyrie PM, Quinn NP, Jenner P, Marsden CD (1996) Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Mov Disord 11:522–532CrossRefPubMedGoogle Scholar
  56. 56.
    Waldner R, Puschban Z, Scherfler C, Seppi K, Jellinger K, Poewe W, Wenning GK (2001) No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). Neuroscience 102:581–592CrossRefPubMedGoogle Scholar
  57. 57.
    Stefanova N, Puschban Z, Fernagut PO, Brouillet E, Tison F, Reindl M, Jellinger KA, Poewe W, Wenning GK (2003) Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). Acta Neuropathol 106:157–166CrossRefPubMedGoogle Scholar
  58. 58.
    Fernagut PO, Diguet E, Bioulac B, Tison F (2004) MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration. Exp Neurol 185:47–62CrossRefPubMedGoogle Scholar
  59. 59.
    Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Spooren W, Fuss B, Mallon B, Macklin WB, Fujiwara H et al (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3:583–588CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Refolo V, Bez F, Polissidis A, Kuzdas-Wood D, Sturm E, Kamaratou M, Poewe W, Stefanis L, Angela Cenci M, Romero-Ramos M et al (2018) Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. Acta Neuropathol Commun 6:2CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Shults CW, Rockenstein E, Crews L, Adame A, Mante M, Larrea G, Hashimoto M, Song D, Iwatsubo T, Tsuboi K, Masliah E (2005) Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 25:10689–10699CrossRefPubMedGoogle Scholar
  62. 62.
    Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K, Trojanowski JQ, Lee VM (2005) Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45:847–859CrossRefPubMedGoogle Scholar
  63. 63.
    Mandel RJ, Marmion DJ, Kirik D, Chu Y, Heindel C, McCown T, Gray SJ, Kordower JH (2017) Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun 5:47CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Bassil F, Guerin PA, Dutheil N, Li Q, Klugmann M, Meissner WG, Bezard E, Fernagut PO (2017) Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy. Mov Disord 32:1230–1239CrossRefPubMedGoogle Scholar
  65. 65.
    Stefanova N, Reindl M, Poewe W, Wenning GK (2005) In vitro models of multiple system atrophy. Mov Disord 20(Suppl 12):S53–S56CrossRefPubMedGoogle Scholar
  66. 66.
    Kragh CL, Lund LB, Febbraro F, Hansen HD, Gai WP, El-Agnaf O, Richter-Landsberg C, Jensen PH (2009) Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 284:10211–10222CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    May VE, Ettle B, Poehler AM, Nuber S, Ubhi K, Rockenstein E, Winner B, Wegner M, Masliah E, Winkler J (2014) alpha-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy. Neurobiol Aging 35:2357–2368CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Valera E, Spencer B, Mott J, Trejo M, Adame A, Mante M, Rockenstein E, Troncoso JC, Beach TG, Masliah E, Desplats P (2017) MicroRNA-101 modulates autophagy and oligodendroglial alpha-synuclein accumulation in multiple system atrophy. Front Mol Neurosci 10:329CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Grskovic M, Javaherian A, Strulovici B, Daley GQ (2011) Induced pluripotent stem cells—opportunities for disease modelling and drug discovery. Nat Rev Drug Discov 10:915–929CrossRefPubMedGoogle Scholar
  70. 70.
    Khurana V, Tardiff DF, Chung CY, Lindquist S (2015) Toward stem cell-based phenotypic screens for neurodegenerative diseases. Nat Rev Neurol 11:339–350CrossRefPubMedGoogle Scholar
  71. 71.
    LaMarca EA, Powell SK, Akbarian S, Brennand KJ (2018) Modeling neuropsychiatric and neurodegenerative diseases with induced pluripotent stem cells. Front Pediatr 6:82CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998) Embryonic stem cell lines derived from human blastocysts. Science 282:1145–1147CrossRefPubMedGoogle Scholar
  73. 73.
    Evans MJ, Kaufman MH (1981) Establishment in culture of pluripotential cells from mouse embryos. Nature 292:154–156CrossRefPubMedGoogle Scholar
  74. 74.
    Barker RA, Götz M, Parmar M (2018) New approaches for brain repair-from rescue to reprogramming. Nature 557:329–334CrossRefPubMedGoogle Scholar
  75. 75.
    McLaren A (2001) Ethical and social considerations of stem cell research. Nature 414:129–131CrossRefPubMedGoogle Scholar
  76. 76.
    Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676CrossRefPubMedGoogle Scholar
  77. 77.
    Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872CrossRefPubMedGoogle Scholar
  78. 78.
    Malik N, Rao MS (2013) A review of the methods for human iPSC derivation. Methods Mol Biol 997:23–33CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Hu BY, Weick JP, Yu J, Ma LX, Zhang XQ, Thomson JA, Zhang SC (2010) Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci USA 107:4335–4340CrossRefPubMedGoogle Scholar
  80. 80.
    Perrier AL, Tabar V, Barberi T, Rubio ME, Bruses J, Topf N, Harrison NL, Studer L (2004) Derivation of midbrain dopamine neurons from human embryonic stem cells. PNAS 34:12543–12548CrossRefGoogle Scholar
  81. 81.
    Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27:275–280CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A et al (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480:547–551CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Kirkeby A, Grealish S, Wolf DA, Nelander J, Wood J, Lundblad M, Lindvall O, Parmar M (2012) Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep 1:703–714CrossRefPubMedGoogle Scholar
  84. 84.
    Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M et al (2009) Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136:964–977CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Miller JD, Ganat YM, Kishinevsky S, Bowman RL, Liu B, Tu EY, Mandal PK, Vera E, Shim JW, Kriks S et al (2013) Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13:691–705CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Ren Y, Jiang H, Hu Z, Fan K, Wang J, Janoschka S, Wang X, Ge S, Feng J (2015) Parkin mutations reduce the complexity of neuronal processes in iPSC-derived human neurons. Stem Cells 33:68–78CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, McLean JR, Carrillo-Reid L, Xie Z, Osborn T et al (2012) Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease. Sci Transl Med 4:141ra190CrossRefGoogle Scholar
  88. 88.
    Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, Kee K, Schüle B, Dolmetsch RE, Langston W et al (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8:267–280CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M, Hu Z, Azabdaftari G, Nakaso K, Yan Z, Feng J (2012) Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat Commun 3:668CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Ryan SD, Dolatabadi N, Chan SF, Zhang X, Akhtar MW, Parker J, Soldner F, Sunico CR, Nagar S, Talantova M et al (2013) Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell 155:1351–1364CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, Nihira T, Kobayashi T, Ohyama M, Sato S et al (2012) Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain 5:35CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, Cavaleri F, Nagano M, Drummond NJ, Taanman JW et al (2011) Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun 2:440CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D (2011) Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci 31:5970–5976CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Shaltouki A, Sivapatham R, Pei Y, Gerencser AA, Momčilović O, Rao MS, Zeng X (2015) Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines. Stem Cell Rep 4:847–859CrossRefGoogle Scholar
  95. 95.
    Aflaki E, Borger DK, Moaven N, Stubblefield BK, Rogers SA, Patnaik S, Schoenen FJ, Westbroek W, Zheng W, Sullivan P et al (2016) A new glucocerebrosidase chaperone reduces α-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with gaucher disease and parkinsonism. J Neurosci 36:7441–7452CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Woodard CM, Campos BA, Kuo SH, Nirenberg MJ, Nestor MW, Zimmer M, Mosharov EV, Sulzer D, Zhou H, Paull D et al (2014) iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson’s disease. Cell Rep 9:1173–1182CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Schöndorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, Sardi SP, Valsecchi M, Hoffmann S, Schwarz LK et al (2014) iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun 5:4028CrossRefPubMedGoogle Scholar
  98. 98.
    Fernández-Santiago R, Carballo-Carbajal I, Castellano G, Torrent R, Richaud Y, Sánchez-Danés A, Vilarrasa-Blasi R, Sánchez-Pla A, Mosquera JL, Soriano J et al (2015) Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson’s disease patients. EMBO Mol Med 7:1529–1546CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Douvaras P, Wang J, Zimmer M, Hanchuk S, O’Bara MA, Sadiq S, Sim FJ, Goldman J, Fossati V (2014) Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. Stem Cell Rep 3:250–259CrossRefGoogle Scholar
  100. 100.
    Nevin ZS, Factor DC, Karl RT, Douvaras P, Laukka J, Windrem MS, Goldman SA, Fossati V, Hobson GM, Tesar PJ (2017) Modeling the mutational and phenotypic landscapes of Pelizaeus–Merzbacher disease with human iPSC-derived oligodendrocytes. Am J Hum Genet 100:617–634CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Douvaras P, Sun B, Wang M, Kruglikov I, Lallos G, Zimmer M, Terrenoire C, Zhang B, Gandy S, Schadt E et al (2017) Directed differentiation of human pluripotent stem cells to microglia. Stem Cell Rep 8:1516–1524CrossRefGoogle Scholar
  102. 102.
    Tcw J, Wang M, Pimenova AA, Bowles KR, Hartley BJ, Lacin E, Machlovi SI, Abdelaal R, Karch CM, Phatnani H et al (2017) An efficient platform for astrocyte differentiation from human induced pluripotent stem cells. Stem Cell Rep 9:600–614CrossRefGoogle Scholar
  103. 103.
    Peng C, Gathagan RJ, Covell DJ, Medellin C, Stieber A, Robinson JL, Zhang B, Pitkin RM, Olufemi MF, Luk KC et al (2018) Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. Nature 557:558–563CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Solano SM, Miller DW, Augood SJ, Young AB, Penney JB (2000) Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson’s disease. Ann Neurol 47:201–210CrossRefPubMedGoogle Scholar
  105. 105.
    Djelloul M, Holmqvist S, Boza-Serrano A, Azevedo C, Yeung MS, Goldwurm S, Frisén J, Deierborg T, Roybon L (2015) Alpha-synuclein expression in the oligodendrocyte lineage: an in vitro and in vivo study using rodent and human models. Stem Cell Rep 5:174–184CrossRefGoogle Scholar
  106. 106.
    Stacpoole SR, Spitzer S, Bilican B, Compston A, Karadottir R, Chandran S, Franklin RJ (2013) High yields of oligodendrocyte lineage cells from human embryonic stem cells at physiological oxygen tensions for evaluation of translational biology. Stem Cell Rep 1:437–450CrossRefGoogle Scholar
  107. 107.
    Richter-Landsberg C, Gorath M, Trojanowski JQ, Lee VM (2000) Alpha-synuclein is developmentally expressed in cultured rat brain oligodendrocytes. J Neurosci Res 62:9–14CrossRefPubMedGoogle Scholar
  108. 108.
    Kaji S, Maki T, Kinoshita H, Uemura N, Ayaki T, Kawamoto Y, Furuta T, Urushitani M, Hasegawa M, Kinoshita Y et al (2018) Pathological endogenous α-synuclein accumulation in oligodendrocyte precursor cells potentially induces inclusions in multiple system atrophy. Stem Cell Rep 10:356–365CrossRefGoogle Scholar
  109. 109.
    Blin O, Desnuelle C, Rascol O, Borg M, Peyro Saint Paul H, Azulay JP, Billé F, Figarella D, Coulom F, Pellissier JF (1994) Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson’s disease and multiple system atrophy. J Neurol Sci 125:95–101CrossRefPubMedGoogle Scholar
  110. 110.
    Gu M, Gash MT, Cooper JM, Wenning GK, Daniel SE, Quinn NP, Marsden CD, Schapira AH (1997) Mitochondrial respiratory chain function in multiple system atrophy. Mov Disord 12:418–422CrossRefPubMedGoogle Scholar
  111. 111.
    Ghorayeb I, Fernagut PO, Hervier L, Labattu B, Bioulac B, Tison F (2002) A ‘single toxin-double lesion’ rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis. Neuroscience 115:533–546CrossRefPubMedGoogle Scholar
  112. 112.
    Nakamoto FK, Okamoto S, Mitsui J, Sone T, Ishikawa M, Yamamoto Y, Kanegae Y, Nakatake Y, Imaizumi K, Ishiura H et al (2018) The pathogenesis linked to coenzyme Q10 insufficiency in iPSC-derived neurons from patients with multiple-system atrophy. Sci Rep 8:14215CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Imaizumi K, Sone T, Ibata K, Fujimori K, Yuzaki M, Akamatsu W, Okano H (2015) Controlling the regional identity of hPSC-derived neurons to uncover neuronal subtype specificity of neurological disease phenotypes. Stem Cell Rep 5:1010–1022CrossRefGoogle Scholar
  114. 114.
    Numasawa-Kuroiwa Y, Okada Y, Shibata S, Kishi N, Akamatsu W, Shoji M, Nakanishi A, Oyama M, Osaka H, Inoue K et al (2014) Involvement of ER stress in dysmyelination of Pelizaeus–Merzbacher disease with PLP1 missense mutations shown by iPSC-derived oligodendrocytes. Stem Cell Rep 2:648–661CrossRefGoogle Scholar
  115. 115.
    Monzio Compagnoni G, Kleiner G, Samarani M, Aureli M, Faustini G, Bellucci A, Ronchi D, Bordoni A, Garbellini M, Salani S et al (2018) Mitochondrial dysregulation and impaired autophagy in iPSC-derived dopaminergic neurons of multiple system atrophy. Stem Cell Rep 11:1185–1198CrossRefGoogle Scholar
  116. 116.
    Ronchi D, Di Biase E, Franco G, Melzi V, Del Sorbo F, Elia A, Barzaghi C, Garavaglia B, Bergamini C, Fato R et al (2016) Mutational analysis of COQ2 in patients with MSA in Italy. Neurobiol Aging 45:213.e211–213.e212CrossRefGoogle Scholar
  117. 117.
    Zhang P, Xia N, Reijo Pera RA (2014) Directed dopaminergic neuron differentiation from human pluripotent stem cells. J Vis Exp 2014:51737Google Scholar
  118. 118.
    Schottlaender LV, Bettencourt C, Kiely AP, Chalasani A, Neergheen V, Holton JL, Hargreaves I, Houlden H (2016) Coenzyme Q10 levels are decreased in the cerebellum of multiple-system atrophy patients. PLoS One 11:e0149557CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Barca E, Kleiner G, Tang G, Ziosi M, Tadesse S, Masliah E, Louis ED, Faust P, Kang UJ, Torres J et al (2016) Decreased coenzyme Q10 levels in multiple system atrophy cerebellum. J Neuropathol Exp Neurol 75:663–672CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Monzio Compagnoni G, Kleiner G, Bordoni A, Fortunato F, Ronchi D, Salani S, Guida M, Corti C, Pichler I, Bergamini C et al (2018) Mitochondrial dysfunction in fibroblasts of multiple system atrophy. Biochim Biophys Acta Mol Basis Dis 1864:3588–3597CrossRefPubMedGoogle Scholar
  121. 121.
    Hockemeyer D, Jaenisch R (2016) Induced pluripotent stem cells meet genome editing. Cell Stem Cell 18:573–586CrossRefPubMedPubMedCentralGoogle Scholar
  122. 122.
    Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, Smith ZD, Ziller M, Croft GF, Amoroso MW, Oakley DH et al (2011) Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 144:439–452CrossRefPubMedPubMedCentralGoogle Scholar
  123. 123.
    Nefzger CM, Rossello FJ, Chen J, Liu X, Knaupp AS, Firas J, Paynter JM, Pflueger J, Buckberry S, Lim SM et al (2017) Cell type of origin dictates the route to pluripotency. Cell Rep 21:2649–2660CrossRefPubMedGoogle Scholar
  124. 124.
    Chen AE, Egli D, Niakan K, Deng J, Akutsu H, Yamaki M, Cowan C, Fitz-Gerald C, Zhang K, Melton DA, Eggan K (2009) Optimal timing of inner cell mass isolation increases the efficiency of human embryonic stem cell derivation and allows generation of sibling cell lines. Cell Stem Cell 4:103–106CrossRefPubMedPubMedCentralGoogle Scholar
  125. 125.
    Lancaster MA, Knoblich JA (2014) Organogenesis in a dish: modeling development and disease using organoid technologies. Science 345:1247125CrossRefPubMedGoogle Scholar
  126. 126.
    Madhavan M, Nevin ZS, Shick HE, Garrison E, Clarkson-Paredes C, Karl M, Clayton BLL, Factor DC, Allan KC, Barbar L et al (2018) Induction of myelinating oligodendrocytes in human cortical spheroids. Nat Methods 15:700–706CrossRefPubMedPubMedCentralGoogle Scholar
  127. 127.
    Lancaster MA, Knoblich JA (2014) Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc 9:2329–2340CrossRefPubMedPubMedCentralGoogle Scholar
  128. 128.
    Jo J, Xiao Y, Sun AX, Cukuroglu E, Tran HD, Göke J, Tan ZY, Saw TY, Tan CP, Lokman H et al (2016) Midbrain-like organoids from human pluripotent stem cells contain functional dopaminergic and neuromelanin-producing neurons. Cell Stem Cell 19:248–257CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Division of Neurobiology, Department of NeurologyMedical University of InnsbruckInnsbruckAustria

Personalised recommendations